Know Labs Stock Price, News & Analysis

Know Labs (NYSE American: KNW) announced the adjournment of its Special Meeting of Stockholders originally scheduled for July 24, 2025. The meeting will be reconvened on July 31, 2025, at 1:30 p.m. Pacific Time virtually.

The record date remains June 20, 2025, and stockholders who haven't voted are encouraged to vote "FOR" each proposal. Previously cast votes will remain valid unless changed. Stockholders can vote via internet at www.proxyvote.com or by telephone at 1-800-690-6903 until 11:59 p.m. Eastern time on July 30, 2025.

Know Labs (NYSE American: KNW) has issued a reminder to stockholders to vote ahead of their Special Meeting scheduled for July 24, 2025 at 1:30 p.m. Pacific time. The virtual meeting is open to stockholders of record as of June 20, 2025.

Stockholders can cast their votes through multiple channels including online at www.proxyvote.com or by phone at 1-800-690-6903. The deadline for internet and telephone voting is 11:59 p.m. Eastern time on July 23, 2025. The Company's Board of Directors unanimously recommends voting "FOR" each proposal.

Know Labs (NYSE: KNW) announced a significant strategic shift as Greg Kidd, former Ripple Chief Risk Officer, through Goldeneye 1995 LLC, will acquire controlling interest in the company at $0.335 per share. The deal includes 1,000 Bitcoin (valued at ~$105M) plus cash for debt retirement and working capital. Kidd will become CEO and Chairman, implementing a Bitcoin treasury strategy where Bitcoin will constitute 82% of market cap with a 1.22x implied entry mNAV multiple. Current founder Ron Erickson will transition to Vice Chairman and President of a new division focused on continuing the company's non-invasive diagnostic research. The transaction, unanimously approved by the board, is expected to close in Q3 2025 pending shareholder approval.

Know Labs (NYSE: KNW) has announced successful laboratory research using its patented Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology to identify real-time pH level changes. The research demonstrates a novel contactless approach where the sensor detects changes through a PVC pipe using Linear Discriminant Analysis and Fourier transform of frequency data.

The technology shows promising applications across multiple sectors:

• Medical Diagnostics: For monitoring physiological states and managing health conditions through pH measurements in blood, urine, saliva, and cerebrospinal fluid
• Pharmaceutical Manufacturing: Essential for drug formulation, production processes, and final product testing
• Food Safety and Quality: Critical for controlling product taste, texture, color, shelf-life, and preventing harmful microorganism growth

The company has submitted this research for peer review and launched Know Labs Technology Licensing (KTL) program to enable corporations, universities, and research institutions to utilize RFDS technology across various industries.

Know Labs (NYSE American: KNW) has announced its participation in The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Technology Fair, scheduled for March 19-22, 2025, in Amsterdam, Netherlands. The company, which specializes in non-invasive medical diagnostic technology through its Radio Frequency Dialectic Spectroscopy (RFDS) platform, will present updates on their non-invasive blood glucose monitor development since the previous year's conference.

The company plans to engage with potential strategic partners and industry leaders in diabetes management to explore collaboration opportunities. Following the recent launch of Know Labs Technology Licensing (KTL), the company has established a clear pathway for partnership and licensing arrangements, aimed at accelerating the commercialization of their platform technology.

Know Labs (KNWN) has announced the cancellation of its Special Meeting of Stockholders that was scheduled for March 7, 2025. The meeting was originally intended to seek approval for a reverse stock split. This cancellation follows the company's recent implementation of a 1-for-40 reverse stock split of its authorized and outstanding common stock on February 18, 2025, which became effective February 19, 2025. The company noted that this reverse split did not require stockholder approval.

Know Labs, which recently moved from NYSE American (KNW) to OTC Pink Markets (KNWN), is known for its work in radio frequency dielectric spectroscopy (RFDS) technology.

Know Labs (KNWN) has announced a 1-for-40 reverse stock split of its common stock, effective February 19, 2025. The company's stock will temporarily trade under 'KNWND' for 20 days before reverting to 'KNWN' on the OTC Pink Market. This move follows the company's delisting from NYSE American due to bid prices falling below $0.10.

The company is currently appealing the delisting decision to the NYSE American Listings Qualifications Panel, with trading suspended during the appeal process. The reverse split was implemented by the Board of Directors as part of efforts to regain NYSE American listing compliance. The company expects near-term revenues from its recently announced Know Labs Technology Licensing initiative while continuing its focus on blood glucose monitoring development.

Know Labs (KNWN) reported Q1 FY2025 financial results, showing a net loss of $4.67 million, up 35.4% from $3.45 million in Q1 FY2024. The company recorded a non-cash charge of $2.45 million related to stock-based compensation, debt extinguishment, warrant repricing, and debt issuance costs.

R&D expenses decreased 46.1% to $802,000, while SG&A expenses dropped 2% to $1.97 million. Cash and equivalents stood at $1.03 million as of December 31, 2024, down from $3.11 million on September 30, 2024. The company closed a $300,000 registered direct offering and believes it has sufficient funds to operate until April 30, 2025.

Shareholder equity was negative $3.91 million, and the company's auditors included a going concern warning in their opinion.

Know Labs (KNWN) has announced it will host a webcast on February 14, 2025, at 1:30 PM PT to discuss its first quarter fiscal year 2025 business updates and financial results for the period ended December 31, 2024. The company, which recently moved from NYSE American to OTC Markets, specializes in radio frequency dielectric spectroscopy (RFDS) for non-invasive medical diagnostic technology and has launched the Know Labs Technology Licensing (KTL) initiative.

The live audio webcast will be accessible to media and investors at https://ir.knowlabs.co starting at 1:15 PM PT, with a replay available afterward on the company's website.